Cannabis Global (Cannabis Global) Debt-to-Revenue : 1.34 (As of May. 2022)

View and export this data going back to 2008. Start your Free Trial

What is Cannabis Global Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cannabis Global's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2022 was $3.06 Mil. Cannabis Global's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2022 was $1.17 Mil. Cannabis Global's annualized Revenue for the quarter that ended in May. 2022 was $3.17 Mil. Cannabis Global's annualized Debt-to-Revenue for the quarter that ended in May. 2022 was 1.34.

Cannabis Global Debt-to-Revenue Historical Data

The historical data trend for Cannabis Global's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Global Debt-to-Revenue Chart

Cannabis Global Annual Data

Trend

Aug12

Aug13

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

87.67

2.50

Cannabis Global Quarterly Data
	Aug17	Nov17	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22
Debt-to-Revenue	Get a 7-Day Free Trial															1.09	1.59	1.79	1.68	1.34

Competitive Comparison of Cannabis Global's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Global's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannabis Global's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Global's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cannabis Global's Debt-to-Revenue falls into.

Cannabis Global Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cannabis Global's Debt-to-Revenue for the fiscal year that ended in Aug. 2021 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2.77	+	1.236)	/	1.601
	=	2.50

Cannabis Global's annualized Debt-to-Revenue for the quarter that ended in May. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.058	+	1.174)	/	3.168
	=	1.34

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (May. 2022) Revenue data.

Cannabis Global Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cannabis Global's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannabis Global (Cannabis Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Global Inc (OTCPK:CBGL) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

520 S. Grand Avenue, Suite 320, Los Angeles, CA, USA, 90071

Website

https://www.cannabisglobalinc.com

Cannabis Global manufactures and distributes various cannabis products via its majority ownership of Natural Plant Extract, Inc is developing the Ethos Comply Bag, and generally conducts research and development in the areas of hemp, cannabis and consumer food goods. The company also have an active research and development program primarily focused on creating and commercializing engineered technologies that deliver hemp extracts and cannabinoids to the human body. Its product includes cannabis flower packaged in various weights, cannabis Pre-rolls, cannabis edible products.

Executives

Jim L. Riley	director	C/O CANNABIS GLOBAL INC., 520 S GRAND AVENUE, SUITE 320, LOS ANGELES CA 90071
Ghs Investments, Llc	10 percent owner	0830 SOUTH EASTERN AVENUE, #124-376, LAS VEGAS NV 89123
Hymers Iii R. Leslie	director, 10 percent owner	520 S GRAND AVENUE, STE 320, LOS ANGELES CA 90071
Arman Tabatabaei	director, officer: CEO, CFO	520 SOUTH GRAND AVENUE, SUITE 320, LOS ANGELES CA 90071
Lauderdale Holdings, Llc	director, 10 percent owner, officer: CEO/President/CFO	1919 NW 19 STREET, FT LAUDERDALE FL 33311
Harmel S Rayat	10 percent owner	700 - 688 WEST HASTINGS STREET, VANCOUVER A1 V6B 1P1
David A Gamache	director, officer: SECRETARY/TREASURER/CFO	3905 NATIONAL DRIVE, SUITE 110, BURTONSVILLE MD 20866
Meetesh V Patel	director, officer: PRESIDENT/CEO	8775 CENTRE PARK DRIVE, # 210, COLUMBIA MD 21045
Pattiann Hiranandani	director	3905 NATIONAL DRIVE, BURTONSVILLE MD 20866